Mary Allen

3.1k total citations
57 papers, 1.1k citations indexed

About

Mary Allen is a scholar working on Virology, Molecular Biology and Immunology. According to data from OpenAlex, Mary Allen has authored 57 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Virology, 17 papers in Molecular Biology and 17 papers in Immunology. Recurrent topics in Mary Allen's work include HIV Research and Treatment (24 papers), vaccines and immunoinformatics approaches (13 papers) and Food Allergy and Anaphylaxis Research (13 papers). Mary Allen is often cited by papers focused on HIV Research and Treatment (24 papers), vaccines and immunoinformatics approaches (13 papers) and Food Allergy and Anaphylaxis Research (13 papers). Mary Allen collaborates with scholars based in United States, South Africa and Canada. Mary Allen's co-authors include Ann E. Clarke, Reza Alizadehfar, Melissa Wake, Kylie D. Hesketh, Moshe Ben‐Shoshan, Laurie Harada, Yvan St‐Pierre, Peter B. Gilbert, Lawrence Joseph and Yuka Asai and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Investigation and SHILAP Revista de lepidopterología.

In The Last Decade

Mary Allen

50 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mary Allen United States 19 350 312 292 220 220 57 1.1k
Maria Ilma Araújo Brazil 22 35 0.1× 265 0.8× 154 0.5× 167 0.8× 427 1.9× 60 1.9k
Emmanuel Hermann France 20 68 0.2× 138 0.4× 45 0.2× 356 1.6× 492 2.2× 41 1.2k
Manale Harfouche Qatar 18 96 0.3× 169 0.5× 19 0.1× 787 3.6× 135 0.6× 34 1.2k
Irja Davidkin Finland 25 70 0.2× 890 2.9× 77 0.3× 1.4k 6.2× 262 1.2× 43 2.0k
A. Decoster France 20 204 0.6× 199 0.6× 28 0.1× 842 3.8× 90 0.4× 52 1.4k
J. Donald Millar United States 17 862 2.5× 614 2.0× 24 0.1× 602 2.7× 264 1.2× 35 1.7k
Phillip LaRussa United States 10 228 0.7× 169 0.5× 41 0.1× 682 3.1× 113 0.5× 16 862
Daniel Pilger Germany 20 39 0.1× 390 1.3× 51 0.2× 162 0.7× 122 0.6× 47 886
Margot Whitfeld Australia 20 111 0.3× 1.3k 4.1× 41 0.1× 215 1.0× 46 0.2× 51 1.7k
Marta Heloísa Lopes Brazil 20 90 0.3× 298 1.0× 20 0.1× 1.2k 5.3× 147 0.7× 75 1.6k

Countries citing papers authored by Mary Allen

Since Specialization
Citations

This map shows the geographic impact of Mary Allen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Allen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Allen more than expected).

Fields of papers citing papers by Mary Allen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Allen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Allen. The network helps show where Mary Allen may publish in the future.

Co-authorship network of co-authors of Mary Allen

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Allen. A scholar is included among the top collaborators of Mary Allen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Allen. Mary Allen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Barone, G., et al.. (2025). LIET model: capturing the kinetics of RNA polymerase from loading to termination. Nucleic Acids Research. 53(7).
2.
3.
Dowell, Robin D., et al.. (2025). DYRK1A in blood and immune function: implications in leukemia, inflammatory disorders, infection and Down syndrome. Frontiers in Cell and Developmental Biology. 13. 1587089–1587089.
4.
Damon, Leah J., Lynn Sanford, Taylor Jones, et al.. (2024). Cellular zinc status alters chromatin accessibility and binding of p53 to DNA. Life Science Alliance. 7(9). e202402638–e202402638. 4 indexed citations
5.
Hural, John, Ole Lagatie, Ludo Lavreys, et al.. (2024). HIV Diagnostics and Vaccines: It Takes Two to Tango. The Journal of Infectious Diseases. 229(6). 1919–1925. 3 indexed citations
6.
Laher, Fatima, et al.. (2022). Use of Varied Screening Risk Criteria and HIV Incidence in Phase 1 and 2 HIV Vaccine Trials in South Africa. AIDS and Behavior. 27(4). 1314–1320.
7.
Curlin, Marcel E., Jason Shao, Gabriela Diaz, et al.. (2020). Long-term mucosal T cell activation and homing phenotypes in recipients of an Ad5-vectored HIV vaccine. Vaccine. 38(36). 5814–5821. 2 indexed citations
8.
Andrasik, Michele P., Doug Grove, Gail Broder, et al.. (2019). A descriptive analysis of transgender participants in phase 1-2a trials of the HIV Vaccine Trials Network (HVTN) in the United States and Peru. Vaccine. 37(29). 3911–3917. 3 indexed citations
9.
Moodie, Zoe, Barbara Metch, Linda‐Gail Bekker, et al.. (2015). Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men. PLoS ONE. 10(9). e0137666–e0137666. 25 indexed citations
10.
Bart, Pierre‐Alexandre, Yunda Huang, Shelly Karuna, et al.. (2014). HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial. Journal of Clinical Investigation. 124(11). 4843–4856. 18 indexed citations
11.
Gray, Glenda, Zoe Moodie, Barbara Metch, et al.. (2014). Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. The Lancet Infectious Diseases. 14(5). 388–396. 82 indexed citations
12.
Hay, Christine M., Gregory J. Wilson, Marnie Elizaga, et al.. (2014). An HIV DNA Vaccine Delivered by Electroporation and Boosted by rVSV HIV-1 Gag Is Safe and Immunogenic in Healthy HIV-uninfected Adults. AIDS Research and Human Retroviruses. 30(S1). A17–A17. 1 indexed citations
13.
Ben‐Shoshan, Moshe, Reza Alizadehfar, Lawrence Joseph, et al.. (2011). Inadvertent exposures in children with peanut allergy. Pediatric Allergy and Immunology. 23(2). 134–140. 74 indexed citations
14.
Waserman, Susan, Rhoda Kagan, Reza Alizadehfar, et al.. (2010). Role of food labels in accidental exposures in food-allergic individuals in Canada. Annals of Allergy Asthma & Immunology. 104(1). 60–65. 76 indexed citations
15.
Allen, Mary & Chuen‐Yen Lau. (2008). Social impact of preventive HIV vaccine clinical trial participation: A model of prevention, assessment and intervention. Social Science & Medicine. 66(4). 945–951. 24 indexed citations
16.
Cleghorn, Farley, Jean W. Pape, Mauro Schechter, et al.. (2007). Lessons From a Multisite International Trial in the Caribbean and South America of an HIV-1 Canarypox Vaccine (ALVAC-HIV vCP1452) With or Without Boosting With MN rgp120. JAIDS Journal of Acquired Immune Deficiency Syndromes. 46(2). 222–230. 25 indexed citations
17.
Rodriguez‐Chavez, Isaac R., Mary Allen, Edgar L. Hill, et al.. (2006). Current advances and challenges in HIV-1 vaccines. Current HIV/AIDS Reports. 3(1). 39–47. 11 indexed citations
18.
Ackers, Marta‐Louise, Bharat Parekh, Thomas G. Evans, et al.. (2003). Human Immunodeficiency Virus (HIV) Seropositivity among Uninfected HIV Vaccine Recipients. The Journal of Infectious Diseases. 187(6). 879–886. 31 indexed citations
19.
Gilbert, Peter B., Ya Lin Chiu, Mary Allen, et al.. (2003). Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials. Vaccine. 21(21-22). 2933–2947. 55 indexed citations
20.
Allen, Mary, et al.. (2001). Trial-Related Discrimination in HIV Vaccine Clinical Trials. AIDS Research and Human Retroviruses. 17(8). 667–674. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maria Ilma Araújo Breakdown of academic impact, for papers by Emmanuel Hermann Breakdown of academic impact, for papers by Manale Harfouche Breakdown of academic impact, for papers by Irja Davidkin Breakdown of academic impact, for papers by A. Decoster Breakdown of academic impact, for papers by J. Donald Millar Breakdown of academic impact, for papers by Phillip LaRussa Breakdown of academic impact, for papers by Daniel Pilger Breakdown of academic impact, for papers by Margot Whitfeld Breakdown of academic impact, for papers by Marta Heloísa Lopes
Rankless by CCL
2026